PacBio partners with Lucid Genomics for long-read sequencing analysis

PacBio (NASDAQ: PACB) announced that Lucid Genomics GmbH has joined its Compatible partner program to provide tertiary analysis solutions for long-read sequencing data.

The collaboration enables Lucid Genomics' bioinformatics platform to work with PacBio's HiFi sequencing technology for genomic data analysis. Tertiary analysis translates processed genomic data into biological insights through annotation, interpretation, and reporting of genomic variants.

Lucid Genomics' platform supports alignment, phasing, variant annotation, methylation analysis, and visualization tasks designed for PacBio HiFi reads. The integration provides laboratories with a pipeline from sequencer to clinical or research report.

"Being recognized as a PacBio Compatible partner is a significant milestone for Lucid Genomics and for our customers," said Dr. Uira Souto Melo, Founder and CEO of Lucid Genomics. "Long-read sequencing is unlocking parts of the genome that were simply invisible before: non-coding regions, methylation patterns, structural variants in the dark genome."

Dave Miller, Vice President of Global Marketing at PacBio, said the company is "committed to building a strong ecosystem of compatible solutions that enable our customers to fully realize the value of HiFi sequencing across the entire workflow."

The Compatible partner program recognizes third-party providers whose solutions work with PacBio instruments and data formats. Lucid Genomics offers a cloud-native platform for secondary and tertiary analysis for clinical laboratories, research institutions, and biotechnology companies.

The companies may collaborate on customer engagements, technical resources, and marketing initiatives for HiFi sequencing users, according to the press release statement.

You May Also Be Interested In

• Walmart to pay $1.4 billion for Vibe.co acquisition - WSJ
• Pfizer executive says China now leads Europe in drug innovation
• Zeta Surgical begins TMS navigation treatments at Hope Therapeutics clinics